Follicular lymphoma with histologic transformation may merit ASCTJune 14, 2016Indolent LymphomaAggressive Lymphomas
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphomaJune 10, 2016Aggressive Lymphomas
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomasJune 10, 2016Aggressive Lymphomas
Epstein-Barr virus DNA in plasma reliably detects EBV-positive lymphoproliferative disordersMay 11, 2016Indolent LymphomaAggressive Lymphomas
Low transformation rate in nodular lymphocyte–predominant Hodgkin lymphomaApril 28, 2016Indolent Lymphoma
Dose-escalated blinatumomab plus dexamethasone induced responses in relapsed/refractory DLBCLApril 22, 2016Aggressive Lymphomas
FDG-PET guides need for eBEACOPP in advanced Hodgkin’sApril 12, 2016Indolent LymphomaAggressive Lymphomas
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myelomaApril 12, 2016Indolent Lymphoma
